Dr. Samson Fung is board certified oncologist and hematologist, with significant expertise in clinical development, strategic marketing and business development. He has over 20 years of successive experience taking preclinical oncology and immune-oncology therapeutics from preclinical stage, into clinical trials. Some of his early stage developments have reached the market treating patients in need. Apart from advising clients in the area of life sciences, Dr. Fung is the founder & CEO of Susavox Investments. Previously, Dr. Fung has lead Volvox Therapeutics and Susavox Biotechnologies Inc. as founder & CEO & CFO. He spent almost 15 years in various functions in the pharmaceutical and biotech industry peers such as Roche, Novartis, Pharmacia/Pfizer, Novo Nordisk and AstraZeneca. Successful biotechs like Micromet, acquired by AMGEN, accomplish his experience in the field. Dr. Fung graduated from the University of Freiburg, Germany and obtained his board certification in internal medicine with sub-specialisation in oncology and hematology.
